OneDigital Investment Advisors LLC Trims Stake in Insulet Co. (NASDAQ:PODD)

OneDigital Investment Advisors LLC cut its position in shares of Insulet Co. (NASDAQ:PODD) by 3.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 4,572 shares of the medical instruments supplier’s stock after selling 154 shares during the period. OneDigital Investment Advisors LLC’s holdings in Insulet were worth $1,064,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PODD. QRG Capital Management Inc. bought a new position in Insulet in the 3rd quarter worth about $297,000. Diversified Trust Co raised its stake in Insulet by 90.9% during the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after buying an additional 4,348 shares during the last quarter. Natixis bought a new position in shares of Insulet during the 1st quarter valued at $3,610,000. Intech Investment Management LLC boosted its stake in shares of Insulet by 113.8% in the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after buying an additional 3,539 shares during the last quarter. Finally, Seven Eight Capital LP purchased a new stake in Insulet during the first quarter valued at $1,418,000.

Insulet Stock Performance

NASDAQ PODD opened at $260.68 on Tuesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.40. The company has a market cap of $18.28 billion, a P/E ratio of 44.64, a P/E/G ratio of 3.98 and a beta of 1.22. The stock has a 50-day moving average of $238.60 and a two-hundred day moving average of $208.60.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. UBS Group raised their price objective on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. BTIG Research boosted their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Morgan Stanley upped their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Barclays upped their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Sanford C. Bernstein began coverage on shares of Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.